内皮的环氧乙酸释放在过多的阿尔多素中是完整的
Yao Meng1, Aynur Bilyal2, Li Chen2
1Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; Department of Geriatrics, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China.
Atherosclerosis
|September 15, 2024
概括
在原发性阿尔多斯特主义 (PA) 中,环氧乙酸 (EET) 的释放仍然是功能性的. 抑制环氧化酸酶可能会逆转阿尔多斯特诱导的内皮功能障碍,为心血管疾病提供潜在的治疗策略.
科学领域:
- 内分泌学和新陈代谢学
- 心血管研究研究心血管研究
- 血管生物学 血管生物学
背景情况:
- 内皮功能障碍 (ED) 是心血管疾病 (CVD) 的关键因素,与原发性阿尔多斯特隆症 (PA) 相关.
- 在PA相关的ED中,产生有益的脂质介质的环氧乙酸 (EET) 途径在PA相关的ED中的作用尚不清楚.
- 现有研究表明,在实验性高血压模型中,EET途径可能受到干扰.
研究的目的:
- 为了研究暴露于多余阿尔多的人体内皮细胞中EET的产生.
- 为了测量PA患者的循环EET水平.
- 探索阿尔多斯特对内皮细胞的功能影响以及环氧化酶抑制的潜在治疗作用.
主要方法:
- 定量PCR (qPCR) 评估了ETE合成和降解的基因表达.
- 成像评估了内皮功能.
- 质谱学量化了ETE生产和血eicosanoid水平.
- RNA测序提供了机理性的见解.
主要成果:
- 阿尔多斯特暴露诱导了前炎性VCAM1表达和乙胆诱导的反应受损,但没有影响刺激的ETE释放.
- 血eicosanoid度在PA患者和基本高血压对照中是相似的.
- 可溶性环氧化酶抑制逆转了阿尔多诱导的VCAM1上调和正常化的内皮反应,可能通过恢复CHRNE表达.
结论:
- 在多余的阿尔多素存在时,内皮质EET释放被保留.
- 抑制环氧化酶在逆转阿尔多斯特诱导的内皮细胞功能障碍方面表现有前途.
- 这些发现表明,对于PA中ED的新型治疗方法,需要在临床前和临床试验中进一步调查.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
01:33Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
01:17Hormonal Regulation of Blood Pressure
2.5K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.5K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
01:25Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398